WhaTech | June 19, 2017
The U.S. insomnia market projected to reach USD 4.24 billion by 2021 from USD 3.38 billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021. The non-pharmacological treatment market is categorized into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies.
Based on duration, insomnia is divided into three major categories, namely, transient insomnia (less than a month), short term insomnia (between 1 month and 6 months), & chronic insomnia (more than 6 months).
Complete Report on U.S. Insomnia Market spread across 144 Pages, Profiling 10 Companies and Supported with 16 Tables and 33 Figures is now available at this link.
The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years.
The prescription sleep aids segment is categorised into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonists, and other prescription sleep aids.
1 Key Players in the U.S. Insomnia Pharmacological Treatment Market
2 Top Available Mobile Applications for Insomnia
3 Corporate Strategies Followed Within U.S. Insomnia Market
4 Competitive Situations & Trends
5 Product Launches & Approvals
6 Collaborations, Agreements and Partnerships
U.S. insomnia market categorized into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, & alternative therapies. CBTI is highly recommended therapy for insomnia patients due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly.
The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.
Click Now for PDF Sample Download of this Study Report
The over-the-counter sleep aids segment of the U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period.
Reasons attributing to the growth of this market include easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. In 2016, the antihistamines sleep aids segment is expected to hold the largest share of the over-the-counter sleep aids market, whereas, melatonin is expected to grow at the highest CAGR during the forecast period.
Growing awareness about advantages of melaton in like least amount of side effects, reduces stress levels, and its growing consumption driving growth of segment in U.S. Some of key players offering insomnia treatment (pharmacological)include Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.).
Connect for More Details for More Information “U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) – Forecasts to 2021” report @ www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=836710 .
U.S. insomnia market, by type of treatment, to estimate overall market size during 2013 to 2021. This report also covers drivers, restraints, and opportunities of market along with competitive landscape of U.S. insomnia market players. Market Penetration: Comprehensive information regarding products & services offered by top players in U.S. insomnia market. Product Development/Innovation: Detailed insights on research & development activities, & new product launches in U.S. insomnia market
Reasons to access this report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.